NEW YORK, Oct. 8, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 750,000 shares of its common stock, at a price to the public of $7.00 per share, in connection with the Company's recently announced underwritten public offering of 5,000,000 shares of common stock, bringing total gross proceeds from the offering to $40,250,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Aegis Capital Corp. acted as sole book-running manager of the offering. This offering is being made pursuant to a shelf registration statement that the Company previously filed with the Securities and Exchange Commission (SEC) and which became effective on October 3, 2012. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC, and a final prospectus supplement and accompanying base prospectus will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and, when available, electronic copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from the SEC's website at http://www.sec.gov or from Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019 or via telephone at 212-813-1010 or email: email@example.com. This press release is neither an offer to sell nor a solicitation of an offer to buy any of the Company's securities. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful. Further information regarding the offering is contained in the Company's Current Report on Form 8-K to be filed with the SEC and which may be accessed at www.sec.gov . About NeoStem, Inc. NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.